Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Unconventional Biosimilar Wisdom

Don't Assume The US Is Easier For Innovator Product Defenders

Executive Summary

Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run.

You may also be interested in...



Stockwatch: The Complex Biologics Market Is…Complex

The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.

Stockwatch: Amphastar’s Turn Away From Generics

Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.

Stockwatch: Like Moths To The Unvalidated Flame

Leaving the validation of a drug target until the end of Phase III studies is risky, but working on the unvalidated targets identified by others is riskier still.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel